AU2002341938B2 - Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease - Google Patents

Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease Download PDF

Info

Publication number
AU2002341938B2
AU2002341938B2 AU2002341938A AU2002341938A AU2002341938B2 AU 2002341938 B2 AU2002341938 B2 AU 2002341938B2 AU 2002341938 A AU2002341938 A AU 2002341938A AU 2002341938 A AU2002341938 A AU 2002341938A AU 2002341938 B2 AU2002341938 B2 AU 2002341938B2
Authority
AU
Australia
Prior art keywords
inhibitor
subject
camkii
peptide
myocardial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002341938A
Other languages
English (en)
Other versions
AU2002341938A1 (en
Inventor
Mark Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2002341938A1 publication Critical patent/AU2002341938A1/en
Application granted granted Critical
Publication of AU2002341938B2 publication Critical patent/AU2002341938B2/en
Priority to AU2007237240A priority Critical patent/AU2007237240A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
AU2002341938A 2001-10-01 2002-10-01 Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease Ceased AU2002341938B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007237240A AU2007237240A1 (en) 2001-10-01 2007-11-28 Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32657601P 2001-10-01 2001-10-01
US60/326,576 2001-10-01
US32801001P 2001-10-08 2001-10-08
US60/328,010 2001-10-08
PCT/US2002/031496 WO2003029428A2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007237240A Division AU2007237240A1 (en) 2001-10-01 2007-11-28 Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease

Publications (2)

Publication Number Publication Date
AU2002341938A1 AU2002341938A1 (en) 2003-06-26
AU2002341938B2 true AU2002341938B2 (en) 2007-08-30

Family

ID=26985461

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002341938A Ceased AU2002341938B2 (en) 2001-10-01 2002-10-01 Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease

Country Status (14)

Country Link
US (2) US7320959B2 (enExample)
EP (1) EP1439849A4 (enExample)
JP (1) JP2005504829A (enExample)
KR (1) KR20040045041A (enExample)
CN (1) CN1599622A (enExample)
AU (1) AU2002341938B2 (enExample)
BR (1) BR0213043A (enExample)
CA (1) CA2462443A1 (enExample)
IL (1) IL161231A0 (enExample)
MX (1) MXPA04003040A (enExample)
NO (1) NO20041331L (enExample)
NZ (1) NZ532327A (enExample)
PL (1) PL369104A1 (enExample)
WO (1) WO2003029428A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255121A1 (en) * 2004-11-02 2008-10-16 Dainippon Sumitomo Pharma Co., Ltd. Combination Drug for Treating Autoimmune Disease
CN107402307A (zh) * 2008-04-09 2017-11-28 B.R.A.H.M.S 有限公司 用于预测受损峰值耗氧量的内皮素1原
US8841423B2 (en) * 2008-04-28 2014-09-23 University Of Iowa Research Foundation Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
US20090275514A1 (en) * 2008-05-01 2009-11-05 Anderson Mark E Use of calmodulin kinase ii inhibitors to treat or prevent heart muscle inflammation
WO2010135676A1 (en) * 2009-05-22 2010-11-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Engineered biological pacemakers
US8440656B2 (en) * 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
EP3603658B1 (en) 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
CN105517549B (zh) 2013-03-06 2018-11-23 阿略斯泰罗斯医疗公司 CaMKII抑制剂和其用途
DE102014201651A1 (de) * 2014-01-30 2015-07-30 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Isoxazolderivate zur Verwendung bei der Behandlung und/oder Prophylaxe von Herzerkrankungen
CA2960101C (en) 2014-09-05 2024-05-21 Allosteros Therapeutics, Inc. Substituted carboline derivative and compositions thereof useful as camkii inhibitors
WO2018031771A1 (en) 2016-08-11 2018-02-15 University Of Iowa Research Foundation CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA
CN112972447B (zh) * 2021-03-02 2022-09-23 扬州大学附属医院 CaMK II抑制剂在制备预防和/或治疗急性胰腺炎的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033491A2 (en) * 1997-01-31 1998-08-06 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
JPH11152298A (ja) * 1997-11-19 1999-06-08 Agency Of Ind Science & Technol カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) * 1968-10-17 1970-08-24
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033491A2 (en) * 1997-01-31 1998-08-06 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
US6518245B1 (en) * 1997-01-31 2003-02-11 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
JPH11152298A (ja) * 1997-11-19 1999-06-08 Agency Of Ind Science & Technol カルモジュリン依存性リン酸化酵素ｉｉの特異的阻害剤

Also Published As

Publication number Publication date
EP1439849A2 (en) 2004-07-28
BR0213043A (pt) 2004-10-05
US7632815B2 (en) 2009-12-15
NZ532327A (en) 2005-10-28
US20090011989A1 (en) 2009-01-08
NO20041331D0 (no) 2004-03-31
WO2003029428A8 (en) 2004-04-22
US20040266675A1 (en) 2004-12-30
NO20041331L (no) 2004-05-28
CN1599622A (zh) 2005-03-23
US7320959B2 (en) 2008-01-22
WO2003029428A3 (en) 2003-10-30
WO2003029428A2 (en) 2003-04-10
PL369104A1 (en) 2005-04-18
MXPA04003040A (es) 2004-07-15
EP1439849A4 (en) 2005-09-28
JP2005504829A (ja) 2005-02-17
KR20040045041A (ko) 2004-05-31
IL161231A0 (en) 2004-09-27
CA2462443A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
US7632815B2 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
AU2002337811A1 (en) Adjustable child support structure with accessories
WO2003028507A2 (en) Adjustable child support structure with accessories
Finley et al. Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart
EP1420800B1 (en) Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity
US20090022729A1 (en) Methods and compositions for treating cardiac dysfunctions
AU2002341938A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
Jehle et al. A non-peptide angiotensin II type 2 receptor agonist does not attenuate post-myocardial infarction left ventricular remodeling in mice
US12059403B2 (en) Use of SWELL1 inhibitors and modulators to treat type 2 diabetes and obesity
ES2818556T3 (es) Péptido con eficacia antiobesidad y antidiabética y uso del mismo
ES2958662T3 (es) Tratamiento de cardiopatía por inhibición de la acción de la proteína de anclaje a la cinasa A del músculo (mAKAP)
JP2002528512A (ja) 心臓病及び心不全の治療のためのホスホランバン活性の阻害方法
JP2001515857A (ja) 細胞活性を調節する方法
WO2001032186A2 (en) Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule
CN119112860A (zh) 绿原酸在制备预防或治疗主动脉夹层药物中的应用
Conti et al. Effects of a typical and an atypical antipsychotic on the disruption of prepulse inhibition caused by corticotropin-releasing factor and by rat strain.
AU2007237240A1 (en) Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
CN118141925A (zh) p55γ基因和/或蛋白作为靶点在维持心脏铁稳态及治疗相关病症中的应用
NZ541833A (en) Use of calmodulin kinase II inhibitors, mainly SEQ ID NO:4, to treat myocardial dysfunction in structural heart disease
US20240139229A1 (en) Treatment for aortopathy
EP2671889A2 (en) RF amide-related peptides and methods thereof
US9993516B2 (en) Treatment of left ventricular non-compaction and dilated cardiomyopathy by inhibiting melanocortin receptor four
CN101130069A (zh) 用钙调蛋白激酶ii抑制剂治疗结构性心脏病中的心肌功能障碍
ZA200309727B (en) Method of modulating the activity of calcium channels in cardiac cells and reagents therefor.
AU2002317634B2 (en) Modulation of insulin-regulated aminopeptidase (IRAP)/Angiotensin IV (AT4) receptor activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired